In addition to the current cornerstones of targeted therapy in NSCLC, EGFR mutations and ALK gene fusions, a growing number of alterations, like ROS1 gene fusions, are emerging as treatment predictive in lung cancer broadening the cohort of patients eligible for targeted treatment [1]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.